Crestline Management, LP Clovis Oncology, Inc. Transaction History

Crestline Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $344,921 - $581,093	-11,744 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $493,952 - $732,825	11,744 New	11,744 $534,000
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $923,559 - $1.35 Million	-16,009 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $1.08 Million - $1.36 Million	16,009	16,009 $1.32 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.